- Court
- New York Supreme Court, Appellate Division, First Department
- Case Name
- Lotrean v. 3M Co.
- Slip Op. No.
- 2026 NY Slip Op 03271
- Decision Date
- May 26, 2026
- Docket No.
- Index No. 153361/20, Appeal No. 5138, Case No. 2024-03189
Background
Marinel Lotrean and others brought a toxic tort action against multiple defendants, including E.I. du Pont de Nemours and Company, Rust-Oleum Corporation, and Zep, Inc. Lotrean alleged that he developed Myelodysplastic Syndrome (MDS), a blood cancer, from exposure to solvents contained in the defendants’ products while working at his father’s autobody shop. The defendants moved for summary judgment, submitting expert affidavits and scientific studies demonstrating that the component solvents in their products were not carcinogenic.
In opposition, the plaintiffs’ experts focused on the well-established relationship between exposure to benzene and the risk of developing MDS. However, the plaintiffs’ case was not that the products contained benzene directly, but rather that the solvents in the products were contaminated with benzene. Plaintiffs cited a study showing that component solvents are “often contaminated” by benzene, but did not establish that the solvents in defendants’ specific products were contaminated or, if so, in what amounts. The plaintiffs also pointed to the Peckham study, which concluded that cancers in seven factory workers exposed to toluene were probably caused by toluene contaminated with benzene, but no evidence was presented that those exposures were comparable in manner, amount, or duration to Lotrean’s exposure.
Supreme Court (Bannon, J.) denied the defendants’ summary judgment motions. Defendants appealed.
Holding
The First Department unanimously reversed and granted defendants’ summary judgment motions, dismissing the complaint. The court found that defendants made a prima facie showing of entitlement to summary judgment by demonstrating their component solvents were not carcinogenic. Plaintiffs failed to raise a triable issue of fact on general causation.
The court identified several critical deficiencies in the plaintiffs’ opposition. The plaintiffs’ experts focused on the benzene-MDS relationship rather than demonstrating any link between exposure to the solvents actually contained in the defendants’ products and MDS. While acknowledging that solvents may be contaminated by benzene, the plaintiffs failed to establish that the solvents in these defendants’ products were in fact contaminated or to quantify any contamination. The Peckham study, though showing a connection between toluene contaminated with benzene and cancer, lacked evidence of comparable exposure conditions. The experts’ opinions were based on the unsupported assumption that all solvents are contaminated with benzene. Having found no triable issue on general causation, the court declined to reach the question of specific causation.
Key Takeaways
- In toxic tort cases, plaintiffs must establish general causation—that the specific substances in the defendant’s products can cause the disease—before reaching specific causation questions.
- The Parker v. Mobil Oil Corp. standard requires plaintiffs to demonstrate a link between the particular substances in the defendant’s products and the plaintiff’s condition, not merely a link to a related substance.
- Expert opinions based on unsupported assumptions that all solvents are contaminated with a carcinogenic substance are insufficient to create triable issues of fact.
- Scientific studies cited in opposition to summary judgment must involve comparable exposure conditions to be probative; studies involving different manners, amounts, or durations of exposure may be insufficient.
Why It Matters
This decision applies the Court of Appeals’ seminal Parker v. Mobil Oil Corp. framework and reinforces the rigorous causation standards in toxic tort litigation. The ruling makes clear that plaintiffs cannot establish general causation through a chain of assumptions—here, that solvents may be contaminated with benzene, and benzene causes cancer. Instead, plaintiffs must present evidence that the specific products at issue contained the alleged contaminant in sufficient quantities to cause harm. This decision will be influential in solvent exposure cases and other toxic tort litigation where plaintiffs rely on contamination theories rather than direct evidence of harmful ingredients in the defendant’s products.